TSE:BHC FY2025 EPS Estimate Reduced by Zacks Research

Bausch Health Companies Inc. (TSE:BHC) – Research analysts at Zacks Research lowered their FY2025 EPS estimates for shares of Bausch Health Companies in a report released on Monday, January 20th. Zacks Research analyst R. Department now expects that the company will post earnings per share of $6.06 for the year, down from their prior forecast of $6.13. The consensus estimate for Bausch Health Companies’ current full-year earnings is $5.55 per share. Zacks Research also issued estimates for Bausch Health Companies’ Q4 2025 earnings at $1.68 EPS, Q4 2026 earnings at $1.82 EPS and FY2026 earnings at $7.02 EPS.

Separately, Evercore ISI upgraded shares of Bausch Health Companies to a “hold” rating in a research note on Tuesday, October 15th.

Bausch Health Companies Price Performance

Shares of BHC opened at C$11.12 on Thursday. The firm has a 50-day simple moving average of C$11.24 and a 200-day simple moving average of C$10.33. The company has a debt-to-equity ratio of 7,583.76, a quick ratio of 0.58 and a current ratio of 1.19. The company has a market capitalization of C$4.08 billion, a price-to-earnings ratio of -6.35, a price-to-earnings-growth ratio of 0.21 and a beta of 0.77. Bausch Health Companies has a fifty-two week low of C$5.45 and a fifty-two week high of C$15.43.

Bausch Health Companies (TSE:BHC) last issued its quarterly earnings data on Wednesday, October 30th. The company reported C$1.53 earnings per share for the quarter, beating analysts’ consensus estimates of C$1.43 by C$0.10. The company had revenue of C$3.42 billion during the quarter, compared to analysts’ expectations of C$3.36 billion. Bausch Health Companies had a negative return on equity of 2,304.54% and a negative net margin of 5.12%.

Bausch Health Companies Company Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.